The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells

Toshihiko Sakurai, Vladimir N. Bilim, Andrey V. Ugolkov, Kaori Yuuki, Masaaki Tsukigi, Teiichi Motoyama, Yoshihiko Tomita*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

We investigated a prognostic significance and the mechanism of aberrant nuclear expression of EZH2, a histone methyltransferase, in human renal cell carcinoma (RCC). We found nuclear EZH2 in 48 of 100 RCCs and it was significantly correlated with worse survival in RCC patients. We detected a decreased expression of miR-101 in 15 of 54 RCCs. We found that re-expression of miR-101 resulted in EZH2 depletion and decreased renal cancer cell proliferation. Our results show nuclear EZH2 as a prognostic marker of worse survival in human RCC, and identify miR-101 as a negative regulator of EZH2 expression and renal cancer cell proliferation.

Original languageEnglish (US)
Pages (from-to)607-614
Number of pages8
JournalBiochemical and Biophysical Research Communications
Volume422
Issue number4
DOIs
StatePublished - Jun 15 2012

Keywords

  • Enhancer of zeste homolog 2
  • MicroRNA-101
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells'. Together they form a unique fingerprint.

Cite this